NCT01245049 - Immunogenicity and Safety of GSK Biologicals' Boostrix Polio Vaccine in 3 and 4-year-old Children | Biotech Hunter

Enrollment

387

Participants

Timeline

Start Date

April 1, 2011

Primary Completion Date

March 27, 2012

Study Completion Date

April 2, 2012

Conditions

Acellular PertussisPoliomyelitisTetanusDiphtheria

Interventions

BIOLOGICAL

Boostrix PolioTM

Single dose, intramuscular administration.

BIOLOGICAL

RepevaxTM

Single dose, intramuscular administration.

BIOLOGICAL

PriorixTM

Single dose, intramuscular or subcutaneous administration.

Trial Locations (13)

PL26 7RL

GSK Investigational Site, St Austell

SO16 6YD

GSK Investigational Site, Southampton

BS26 2BJ

GSK Investigational Site, Axbridge

TA1 1XQ

GSK Investigational Site, Taunton

CV9 1EU

GSK Investigational Site, Atherstone

BT19 1PP

GSK Investigational Site, Bangor

BL3 6TL

GSK Investigational Site, Bolton, Nr Manchester

BS2 8AE

GSK Investigational Site, Bristol

M8 9JT

GSK Investigational Site, Crumpsall, Manchester

EX2 5DW

GSK Investigational Site, Exeter

BL1 6AP

GSK Investigational Site, Lancashire

OX3 7LJ

GSK Investigational Site, Oxford

BT41 3AE

GSK Investigational Site, Randalstown